In our hands, the glycolytic capacity of irradiated cancer cells was higher when cells were treated with the PARP inhibitor PJ34 compared with cells receiving irradiation only, corroborating a role of PARP1 activity in the rapid decline of glycolytic activity in irradiated cancer cell line panel. The gene discussed is PARP1; the disease is cancer.